BML-210 Struktur

BML-210

Bezeichnung:BML-210

CAS-Nr537034-17-6

Englisch Name:BML-210

CBNumberCB8254476

SummenformelC20H25N3O2

Molgewicht339.43

MOL-Datei537034-17-6.mol

BML-210 physikalisch-chemischer Eigenschaften

storage temp.	2-8°C
Löslichkeit	DMSO: >20mg/mL
Aggregatzustand	powder
Farbe	white to very faintly yellow
Stabilität	Stable for 2 years from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20° for up to 3 months.

Sicherheit

WGK Germany

Gefahreninformationscode (GHS)

BML-210 Chemische Eigenschaften,Einsatz,Produktion Methoden

Beschreibung
Inhibition of histone deacetylase (HDAC) enzymes by compounds such as trichostatin A can have wide ranging effects in cancer, cell differentiation, and other aspects of gene expression regulation. BML-210 is a small molecule inhibitor of HDAC with an IC₅₀ value of 30 μM when tested in HeLa cell nuclear extracts using 200 μM acetylated fluorometric substrate (substrate available in Cayman’s HDAC Activity and Inhibitor Screening Assay Kits - Item Nos. 10011563 and 10011564).
Verwenden
N1-(2-Aminophenyl)-N8-phenyloctanediamide is a histone deacetylase (HDAC) inhibitor, an anti-cancer target for breast cancer therapeutic intervention.
Definition
ChEBI: A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and 1,2-diaminobenzene.
Biochem/physiol Actions
BML-210 is a synthetic benzamide and is a potential tumor inhibitor. It is used as a therapeutic agent to treat promyelocytic leukemia. In human leukemia cell lines (NB4, HL-60, THP-1, and K562), BML-210 modulates histone deacetylase and promotes apoptosis. BML-210 favors frataxin expression in neurodegenerative disease Friedreich′s ataxia (FRDA). It interacts with myocyte enhancer factor-2 (MEF2) via hydrogen-bonding and prevents histone deacetylase 4 (HDAC4) binding.
Einzelnachweise
1) Savickiene, et al. (2006), The novel histone deacetylase inhibitor BML-210 exerts growth inhibitory, proapoptotic and differentiation stimulating effects on the human leukemia cell lines; Eur. J. Pharmacol. 549 9 2) Herman, et al. (2006), Histone deacetylase inhibitors reverse gene silencing in Friedreich’s ataxia; Nat. Chem. Biol. 10 551

BML-210 Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

537034-17-6, BML-210 Verwandte Suche:

Send Inquriy